KuartisMED, a local health startup focused on neonatal care, raises $1.8 million in seed funding

Founded in 2012, KuartisMED is a biomedical research company that designs, develops, and manufactures smart, safe, and innovative medical products aimed at improving the well-being of newborns, especially premature infants.

The Turkey-based startup KuartisMED has raised $1.8 million in a seed funding round led by Arya Women Investment Platform and APY Ventures. Other participants in the round include Growth Circuit, Techmine, Teknoloji ve İnovasyon Fonu, Teknoloji Yatırım A.Ş., and angel investor Berkay Mollamustafaoğlu.

The newly secured funding will be used to scale the commercialization of its CE-certified product, expand post-sales clinical monitoring, ensure compliance with new markets and regulations, and support marketing and business development activities. The company will also continue to focus on developing new products.

Dr. Ahmet Saracoğlu, Co-founder and CEO of KuartisMED, stated:

“With this investment round, we aim to achieve global growth through international partnerships in the field of neonatology. We will continue to develop pioneering applications and products that enable physicians to make accurate and reliable decisions in a field that is critical for healthcare systems yet receives less attention than it should. With our upcoming digital health product family, we aim to become the first choice for healthcare professionals, newborns, and their families.”

Ahu Serter, Founder of Arya Women Investment Platform, commented:

“Since its establishment, Arya has prioritized gender-balanced entrepreneurship and, in recent years, has focused on technology-driven startups, playing an important role in their growth. We have started investing in deep-tech startups, and KuartisMED is one of them. This investment is important for supporting life sciences and fostering advanced technology startups. Additionally, having esteemed medical professionals like Prof. Dr. Ayşe Nur Ecevit and Prof. Dr. Aylin Tarcan involved in developing technology to prevent neonatal deaths aligns strongly with Arya’s mission.”

Emin Özer, General Manager of Albaraka Portföy, added:

“As APY Ventures, we are pleased to co-lead the investment round of KuartisMED, which operates in the health technologies field. With their NeoSafe product designed for neonatal well-being, they aim to support doctors in discharge decisions for premature infants, potentially reducing complications and mortality rates significantly. Through our Bilişim Vadisi Fund, which focuses on hardware-based healthcare startups, we will continue to support the ecosystem.”

NeoSAFE: KuartisMED’s first product KuartisMED’s first product, NeoSAFE, is a medical device developed to support safe discharge decisions for newborns, particularly premature infants. Founded in 2012, KuartisMED is a biomedical research company that designs and develops innovative medical technologies for neonatal and pediatric care. The company was established by experienced academic physicians Ayşe Nur Ecevit, Aylin Tarcan, and Ahmet Saracoğlu, who specializes in machine learning, computer vision, and signal processing. NeoSAFE was developed with support from programs such as the European Union’s Horizon 2020 SME Instrument and TÜBİTAK TEYDEB R&D and innovation grants. The product focuses on improving the safety and quality of care for newborns, especially the approximately 15 million premature babies born each year worldwide. The device evaluates infants’ feeding ability—also known as feeding maturation—which is critical for successful oral feeding, healthy growth, and safe hospital discharge. NeoSAFE uses non-invasive sensors to monitor babies’ breathing and swallowing activities. These signals are then analyzed באמצעות proprietary machine learning algorithms to generate objective reports on feeding performance, helping healthcare professionals make more accurate clinical decisions.